Compare abrdn Income Credit Strategies Fund (ACP) vs Viatris Inc (VTRS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Viatris Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.23 (market cap $656.21M), while Viatris Inc trades at $16.6 (market cap $19.75B). The key difference: Viatris Inc is far larger — about 30.1× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (17.78%). Which is the better fit depends on your goals.
| ACP | VTRS | |
|---|---|---|
Market Cap | $656.21M | $19.75B |
Sector | Financials | Health |
52-Week High | $5.98 | $17.39 |
52-Week Low | $5.01 | $8.74 |
Dividend Yield | 17.78% | 2.83% |
Enterprise Value | — | $31.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
Viatris (VTRS) trades at $16.96, up 1.56% on the day and near its 52-week high of $17.53. The stock shows a bullish technical trend with consistent earnings beats in recent quarters. However, fundamentals reveal challenges, including a net loss of $3.51 billion in 2025 and negative profit margins, though revenue remains stable around $14.3 billion. Positive developments include a strong pipeline, with recent FDA acceptance of a new drug application for fast-acting meloxicam and positive Phase 3 results for VR-205.
The outlook is mixed; analyst consensus is a 'Hold' with a $20 price target, suggesting modest upside. Key opportunities lie in pipeline catalysts and debt reduction, but risks include persistent profitability issues, high debt levels, and competitive pressures. The stock's valuation metrics like P/S of 1.35 may appeal to value investors, but earnings sustainability is a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
